Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient

Marta Gubbiotti; Barbara Pistilli; Marianna Tudini; Giovanni Benedetti; Eva Galizia; Marco Rusiello; Luciano Latini

doi:10.2217/fon.15.148

Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient

Marta Gubbiotti, Barbara Pistilli, Marianna Tudini, Giovanni Benedetti, Eva Galizia, Marco Rusiello, Luciano Latini

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

The authors present the case of a heavily pretreated young woman with retinal and brain metastases from breast cancer who was successfully treated with eribulin. Eribulin was given at 1.1 mg/m² on day 1 and 8, every 3 weeks for a total of 12 courses. A significant reduction in the size of brain and retinal lesions was achieved after three cycles. The treatment was continued for 12 cycles, with a good profile of tolerability. In this clinical case, eribulin demonstrated to be active on brain and retinal metastases from breast cancer, although preclinical data showed limited ability to cross the blood-brain barrier.

Original language	English
Pages (from-to)	17-22
Number of pages	6
Journal	Future Oncology
Volume	11
Issue number	15s
DOIs	https://doi.org/10.2217/fon.15.148
Publication status	Published - 1 Aug 2015
Externally published	Yes

Keywords

brain metastases
breast cancer
eribulin
retinal metastases

Access to Document

10.2217/fon.15.148

Cite this

@article{7e9734455781496487a9dd42b98ea7d0,

title = "Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient",

abstract = "The authors present the case of a heavily pretreated young woman with retinal and brain metastases from breast cancer who was successfully treated with eribulin. Eribulin was given at 1.1 mg/m2 on day 1 and 8, every 3 weeks for a total of 12 courses. A significant reduction in the size of brain and retinal lesions was achieved after three cycles. The treatment was continued for 12 cycles, with a good profile of tolerability. In this clinical case, eribulin demonstrated to be active on brain and retinal metastases from breast cancer, although preclinical data showed limited ability to cross the blood-brain barrier.",

keywords = "brain metastases, breast cancer, eribulin, retinal metastases",

author = "Marta Gubbiotti and Barbara Pistilli and Marianna Tudini and Giovanni Benedetti and Eva Galizia and Marco Rusiello and Luciano Latini",

note = "Publisher Copyright: {\textcopyright} 2015 Future Medicine Ltd.",

year = "2015",

month = aug,

day = "1",

doi = "10.2217/fon.15.148",

language = "English",

volume = "11",

pages = "17--22",

journal = "Future Oncology",

issn = "1479-6694",

number = "15s",

}

TY - JOUR

T1 - Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient

AU - Gubbiotti, Marta

AU - Pistilli, Barbara

AU - Tudini, Marianna

AU - Benedetti, Giovanni

AU - Galizia, Eva

AU - Rusiello, Marco

AU - Latini, Luciano

PY - 2015/8/1

Y1 - 2015/8/1

N2 - The authors present the case of a heavily pretreated young woman with retinal and brain metastases from breast cancer who was successfully treated with eribulin. Eribulin was given at 1.1 mg/m2 on day 1 and 8, every 3 weeks for a total of 12 courses. A significant reduction in the size of brain and retinal lesions was achieved after three cycles. The treatment was continued for 12 cycles, with a good profile of tolerability. In this clinical case, eribulin demonstrated to be active on brain and retinal metastases from breast cancer, although preclinical data showed limited ability to cross the blood-brain barrier.

AB - The authors present the case of a heavily pretreated young woman with retinal and brain metastases from breast cancer who was successfully treated with eribulin. Eribulin was given at 1.1 mg/m2 on day 1 and 8, every 3 weeks for a total of 12 courses. A significant reduction in the size of brain and retinal lesions was achieved after three cycles. The treatment was continued for 12 cycles, with a good profile of tolerability. In this clinical case, eribulin demonstrated to be active on brain and retinal metastases from breast cancer, although preclinical data showed limited ability to cross the blood-brain barrier.

KW - brain metastases

KW - breast cancer

KW - eribulin

KW - retinal metastases

UR - http://www.scopus.com/inward/record.url?scp=84952659396&partnerID=8YFLogxK

U2 - 10.2217/fon.15.148

DO - 10.2217/fon.15.148

M3 - Article

C2 - 26235260

AN - SCOPUS:84952659396

SN - 1479-6694

VL - 11

SP - 17

EP - 22

JO - Future Oncology

JF - Future Oncology

IS - 15s

ER -

Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient

Abstract

Keywords

Access to Document

Other files and links

Cite this